Works matching DE "GLUCAGON-like peptide-1 receptor"
Results: 1959
Myocardial Protection Against Ischemia-Reperfusion Injury by GLP-1: Molecular Mechanisms.
- Published in:
- Metabolic Syndrome & Related Disorders, 2012, v. 10, n. 6, p. 387, doi. 10.1089/met.2012.0095
- By:
- Publication type:
- Article
Discovery of a potential positive allosteric modulator of glucagon-like peptide 1 receptor through virtual screening and experimental study.
- Published in:
- Journal of Computer-Aided Molecular Design, 2019, v. 33, n. 11, p. 973, doi. 10.1007/s10822-019-00254-4
- By:
- Publication type:
- Article
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer.
- Published in:
- Cancer & Metastasis Reviews, 2024, v. 43, n. 4, p. 1297, doi. 10.1007/s10555-024-10192-9
- By:
- Publication type:
- Article
Glucagon-like Peptide-1 Receptor Agonists and Diabetic Osteopathy: Another Positive Effect of Incretines? A 12 Months Longitudinal Study.
- Published in:
- Calcified Tissue International, 2024, v. 115, n. 2, p. 160, doi. 10.1007/s00223-024-01240-1
- By:
- Publication type:
- Article
Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity.
- Published in:
- Calcified Tissue International, 2024, v. 114, n. 2, p. 86, doi. 10.1007/s00223-023-01150-8
- By:
- Publication type:
- Article
Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Metabolic Bariatric Surgery Takes a Backseat as GLP-1RA Use Rises: Daily Dose.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
Among Stroke Survivors, GLP-1RAs, SGLT2is May Reduce Risk of Future MI, Recurrent Stroke: AHA 2024. Study authors reported a 74% lower risk of death and an 84% lower risk of MI among participants taking either a GLP-1RA or an SGLT2i.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
Metabolic Bariatric Surgery Takes a Backseat as GLP-1RA Use Soars, According to New Research: Clinicians should continue to monitor trade-offs between pharmacologic and surgical management of obesity, researchers said.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
Semaglutide Linked with Reduced Risk of Alzheimer Disease in Large Observational Study.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
Survodutide: Novel GCGR/GLP-1RA Shows Promise in Obesity, MASH Treatment.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
Where is All the Wegovy Going?
- Published in:
- Patient Care (Online), 2024, p. 2
- By:
- Publication type:
- Article
Where is All the Wegovy Going? Highest and Lowest Prescribing States.
- Published in:
- Patient Care (Online), 2024, p. 1
- Publication type:
- Article
FDA Review Suggest No Link Between GLP-1RAs and Suicidal Thoughts but Surveillance Will Continue.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
FDA Review Suggest No Link Between GLP-1RAs and Suicidal Thoughts but Surveillance Will Continue.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
Semaglutide Linked to Lower Risk of Suicidal Ideations in Patients with Obesity, Type 2 Diabetes.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
Long-Term Effects of Incretin-Based Drugs on Glycemic Control in Permanent Neonatal Diabetes.
- Published in:
- JCEM Case Reports, 2024, v. 2, n. 11, p. 1, doi. 10.1210/jcemcr/luae188
- By:
- Publication type:
- Article
Semaglutide for Treating Obesity Induced by Craniopharyngioma Resection: A Successful Case Study.
- Published in:
- JCEM Case Reports, 2023, v. 1, n. 4, p. 1, doi. 10.1210/jcemcr/luad074
- By:
- Publication type:
- Article
Pharmacogenetics of Glucagon-like-peptide-1 receptor in diabetes management.
- Published in:
- Pharmacia (0428-0296), 2023, v. 70, n. 2, p. 383, doi. 10.3897/pharmacia.70.e104481
- By:
- Publication type:
- Article
Obesity A therapeutic target in people with cardiovascular disease.
- Published in:
- Medicine Today, 2024, v. 25, n. 12, p. 23
- By:
- Publication type:
- Article
Skeletal fragility in type 2 diabetes: Assessment and management.
- Published in:
- Medicine Today, 2024, v. 25, n. 7, p. 18
- By:
- Publication type:
- Article
Diabetic kidney disease: A new era in therapeutic management.
- Published in:
- Medicine Today, 2024, v. 25, n. 7, p. 47
- By:
- Publication type:
- Article
Diabetic kidney disease.
- Published in:
- Medicine Today, 2024, v. 25, n. 1/2, p. 47
- By:
- Publication type:
- Article
Preventing diabetic kidney disease progression: An update.
- Published in:
- Medicine Today, 2023, v. 24, n. 11, p. 29
- By:
- Publication type:
- Article
Preventing diabetic kidney disease progression: An update.
- Published in:
- Medicine Today, 2023, v. 24, n. 8, p. 15
- By:
- Publication type:
- Article
Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics.
- Published in:
- European Psychiatry, 2021, v. 64, p. S775, doi. 10.1192/j.eurpsy.2021.2050
- By:
- Publication type:
- Article
Asthma Exacerbations and Glucagon-Like Peptide-1 Receptor Agonists: a Review of the Current Evidence.
- Published in:
- Pulmonary Therapy, 2022, v. 8, n. 4, p. 343, doi. 10.1007/s41030-022-00203-x
- By:
- Publication type:
- Article
SIGNIFICANCE OF SINGLE-NUCLEOTIDE VARIANTS OF ANOREXIGENIC HORMONE GENES IN CHILDHOOD OBESITY.
- Published in:
- Medical Perspectives / Medičnì Perspektivi, 2024, v. 29, n. 1, p. 108, doi. 10.26641/2307-0404.2024.1.300508
- By:
- Publication type:
- Article
A CLINICAL CASE OF ASYMPTOMATIC PANCREATIC HYPERENZYMEMIA ON THE BACKGROUND OF TAKING A GLUCAGON-LIKE PEPTIDE-1 ANALOGUE (GLP-1).
- Published in:
- Medical Perspectives / Medičnì Perspektivi, 2023, v. 28, n. 3, p. 213, doi. 10.26641/2307-0404.2023.3.289229
- By:
- Publication type:
- Article
Is polyethylene glycol loxenatide 100 μg the preferred glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus? A meta-analysis and trial sequential analysis.
- Published in:
- European Review for Medical & Pharmacological Sciences, 2024, v. 28, n. 6, p. 2272
- By:
- Publication type:
- Article
Novel peptidic duaf GLP-1/glucagon receptor agonist alleviates diabetes and diabetic complications in combination with low-intensity ultrasound.
- Published in:
- European Review for Medical & Pharmacological Sciences, 2020, v. 24, n. 23, p. 12423
- By:
- Publication type:
- Article
Liragfutide regulates proliferation, differentiation, and apoptosis of preosteoblasts through a signaling network of Notch/Wnt/Hedgehog signaling pathways.
- Published in:
- European Review for Medical & Pharmacological Sciences, 2020, v. 24, n. 23, p. 12408
- By:
- Publication type:
- Article
Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer's disease.
- Published in:
- Acta Neuropathologica Communications, 2021, v. 9, n. 1, p. 1, doi. 10.1186/s40478-021-01180-z
- By:
- Publication type:
- Article
Fasting plasma c-peptide level predicts the response of glucagon-like peptide-1 agonist (exenatide) add on to metformin monotherapy in obese type 2 diabetics.
- Published in:
- Journal of Experimental & Clinical Medicine / Deneysel ve Klinik Tip Dergisi, 2022, v. 39, n. 3, p. 798, doi. 10.52142/omujecm.39.3.39
- By:
- Publication type:
- Article
Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach.
- Published in:
- Brain Sciences (2076-3425), 2024, v. 14, n. 6, p. 617, doi. 10.3390/brainsci14060617
- By:
- Publication type:
- Article
GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach.
- Published in:
- Brain Sciences (2076-3425), 2023, v. 13, n. 11, p. 1503, doi. 10.3390/brainsci13111503
- By:
- Publication type:
- Article
Comparative Efficacy and Safety of Cardio-Renoprotective Pharmacological Interventions in Chronic Kidney Disease: An Umbrella Review of Network Meta-Analyses and a Multicriteria Decision Analysis.
- Published in:
- Biomolecules (2218-273X), 2025, v. 15, n. 1, p. 39, doi. 10.3390/biom15010039
- By:
- Publication type:
- Article
Biotechnology Revolution Shaping the Future of Diabetes Management.
- Published in:
- Biomolecules (2218-273X), 2024, v. 14, n. 12, p. 1563, doi. 10.3390/biom14121563
- By:
- Publication type:
- Article
Implications of GLP-1 Receptor Agonist on Thyroid Function: A Literature Review of Its Effects on Thyroid Volume, Risk of Cancer, Functionality and TSH Levels.
- Published in:
- Biomolecules (2218-273X), 2024, v. 14, n. 6, p. 687, doi. 10.3390/biom14060687
- By:
- Publication type:
- Article
Beyond the Cardiovascular Effects of Glucagon-like Peptide-1 Receptor Agonists: Body Slimming and Plaque Stabilization. Are New Statins Born?
- Published in:
- Biomolecules (2218-273X), 2023, v. 13, n. 12, p. 1695, doi. 10.3390/biom13121695
- By:
- Publication type:
- Article
Liraglutide Attenuates Glucolipotoxicity-Induced RSC96 Schwann Cells' Inflammation and Dysfunction.
- Published in:
- Biomolecules (2218-273X), 2022, v. 12, n. 10, p. N.PAG, doi. 10.3390/biom12101338
- By:
- Publication type:
- Article
GLP-1 receptor agonist as a modulator of innate immunity.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.997578
- By:
- Publication type:
- Article
Front Cover.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 2, p. C1, doi. 10.1111/dom.14960
- By:
- Publication type:
- Article
Response to letter from Du et al. regarding article 'Sodium‐glucose cotransporter‐2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?'.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 2, p. 630, doi. 10.1111/dom.14913
- By:
- Publication type:
- Article
Comparative effects of weight loss and incretin‐based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 2, p. 570, doi. 10.1111/dom.14903
- By:
- Publication type:
- Article
Glucagon induces the hepatic expression of inflammatory markers in vitro and in vivo.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 2, p. 556, doi. 10.1111/dom.14902
- By:
- Publication type:
- Article
Effects of glucose‐lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta‐analysis of randomized controlled trials with external adjudication of events.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 2, p. 444, doi. 10.1111/dom.14888
- By:
- Publication type:
- Article
Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 2, p. 435, doi. 10.1111/dom.14887
- By:
- Publication type:
- Article
Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon‐like peptide‐1 receptor agonist use.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 2, p. 407, doi. 10.1111/dom.14883
- By:
- Publication type:
- Article
Testing for association between exonic glucagon‐like peptide 1 receptor mutation with physical and brain health traits in UK Biobank.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 2, p. 623, doi. 10.1111/dom.14879
- By:
- Publication type:
- Article